收藏切换
FGFR4: a promising therapeutic target for liver cancer
收藏切换
PDF
Min WANG, Jin-yang ZHANG, Yu-wei WANG, Wen LI, Li-ping SUN*
Acta Pharmaceutica Sinica | 2021, 56(7) : 1832 - 1844
Less
收藏切换
Acta Pharmaceutica Sinica | 2021, 56(7): 1832-1844
Reviews
FGFR4: a promising therapeutic target for liver cancer
Full
Min WANG, Jin-yang ZHANG, Yu-wei WANG, Wen LI, Li-ping SUN*
Affiliations
  • Department of Medicinal Chemistry, College of Pharmacy, Jiangsu Provincial Key Laboratory of Drug Molecular Design and Drug Formation Optimization, China Pharmaceutical University, Nanjing 211198, China
Published: 2021-07-12 doi: 10.16438/j.0513-4870.2020-1944
Outline
收藏切换

Fibroblast growth factor receptor (FGFR), as a member of the receptor tyrosine kinase family, participates in a variety of biological processes by binding to ligand fibroblast growth factors (FGFs) and activating downstream signaling pathways, such as cell proliferation, migration, anti-apoptosis, angiogenesis, etc. FGFR gene amplification, missense mutations, oncogenic fusion are related to the occurrence and development of many cancers. FGFR has become an important potential target in cancer treatment. At present most of these studies focus on FGFR1-3, however there is growing evidence implicating an important and unique role of FGFR4 in oncogenesis and resistance to anti-tumor therapy in multiple types of cancer. The abnormality of FGF19-FGFR4 signaling pathway has been proved to be a carcinogenic factor of liver cancer. Importantly, there are several novel FGFR4-specific inhibitors in clinical trials, FGFR4 is therefore a promising target for the treatment of hepatocellular carcinoma harboring aberrant FGF19-FGFR4 signaling. In this review, we focus on assessing the role of FGFR4 in liver cancer, including a summary of the structure and ligand of FGFR4, downstream signaling pathways, abnormal activation in liver cancer, and the research progress of small molecule FGFR4 inhibitors, FGFR4 monoclonal antibodies and combined immunotherapy.

fibroblast growth factor 19  /  fibroblast growth factor receptor 4  /  liver cancer  /  small molecule inhibitor
Min WANG, Jin-yang ZHANG, Yu-wei WANG, Wen LI, Li-ping SUN. FGFR4: a promising therapeutic target for liver cancer[J]. Acta Pharmaceutica Sinica, 2021 , 56 (7) : 1832 -1844 . DOI: 10.16438/j.0513-4870.2020-1944
Year 2021 volume 56 Issue 7
PDF
179
78
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2020-1944
  • Receive Date:2020-12-19
  • Online Date:2025-12-18
  • Published:2021-07-12
Article Data
Affiliations
History
  • Received:2020-12-19
  • Revised:2021-02-02
Funding
Affiliations
    Department of Medicinal Chemistry, College of Pharmacy, Jiangsu Provincial Key Laboratory of Drug Molecular Design and Drug Formation Optimization, China Pharmaceutical University, Nanjing 211198, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2020-1944
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT